In addition, we performed a meta-analysis by integration of our association prediction and TCGA transcriptome data (see the Methods) to select the top 100 immune-positive MHC I-associated genes to calculate the signature score, termed the MIAS, which is used to predict patient response to anti-PD-1 therapy for a given cancer type (Fig. 1c). The gene discussed is PDCD1; the disease is cancer.